Rock Ventures Iii L.P. Third Sells 55,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Rock Ventures Iii L.P. Third sold 55,000 shares of the business’s stock in a transaction on Monday, January 23rd. The stock was sold at an average price of $9.06, for a total transaction of $498,300.00. Following the completion of the transaction, the insider now owns 5,273,933 shares in the company, valued at approximately $47,781,832.98. The sale was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Rock Ventures Iii L.P. Third also recently made the following trade(s):

• On Friday, January 20th, Rock Ventures Iii L.P. Third sold 100,000 shares of Voyager Therapeutics stock. The stock was sold at an average price of $9.15, for a total transaction of $915,000.00.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $9.48 on Wednesday. The firm has a market cap of $365.99 million, a PE ratio of -20.61 and a beta of 0.92. The firm’s 50-day simple moving average is $6.64 and its 200-day simple moving average is $6.31. Voyager Therapeutics, Inc. has a 1 year low of $2.74 and a 1 year high of $10.81.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.64. The firm had revenue of $41.09 million for the quarter, compared to analyst estimates of $21.25 million. Voyager Therapeutics had a negative net margin of 24.21% and a negative return on equity of 21.97%. On average, equities analysts predict that Voyager Therapeutics, Inc. will post -1.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its stake in Voyager Therapeutics by 1.9% during the third quarter. Price T Rowe Associates Inc. MD now owns 843,711 shares of the company’s stock worth $4,996,000 after acquiring an additional 15,761 shares during the period. Marshall Wace LLP bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $1,123,000. BlackRock Inc. boosted its holdings in Voyager Therapeutics by 4.7% during the third quarter. BlackRock Inc. now owns 590,504 shares of the company’s stock worth $3,496,000 after buying an additional 26,289 shares in the last quarter. Armistice Capital LLC boosted its holdings in Voyager Therapeutics by 32.4% during the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after buying an additional 832,000 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in Voyager Therapeutics by 1,746.8% during the third quarter. Royal Bank of Canada now owns 12,004 shares of the company’s stock worth $71,000 after buying an additional 11,354 shares in the last quarter. Institutional investors and hedge funds own 59.58% of the company’s stock.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.